Circulating CD39+CD8+ T Cells May Predict Better Prognosis and Less Metastasis in Nasopharyngeal Carcinoma Patients
Nasopharyngeal carcinoma (NPC)—a head and neck cancer common in China—has seen major survival improvements with chemoradiotherapy. But distant metastasis remains a critical threat: even after treatment, some patients’ cancer spreads to other organs, lowering their chances of long-term survival. Now, a 2021 study published in the Chinese Medical Journal points to a type of immune cell that could both predict who’s less likely to develop metastasis and explain why some patients respond better to treatment.
The Problem: Metastasis and the Immune System
NPC starts in the nasopharynx (the upper part of the throat behind the nose). For late-stage patients (stages III–IVa), chemoradiotherapy is the standard treatment—but up to 30% still get distant metastasis within 5 years. The immune system plays a key role here: tumor-specific T cells (immune cells that target cancer) are essential for finding and killing spread cancer cells. But not all T cells are equal—some get “exhausted” (lose their ability to fight) or aren’t specific to tumors.
The Study: Focus on CD39+CD8+ T Cells
Researchers from the Third Affiliated Hospital of Xinjiang Medical University, Chinese Academy of Medical Sciences Oxford Institute at the University of Oxford, and other institutions wanted to know if circulating CD39+CD8+ T cells—tumor-specific immune cells that travel in the blood—could predict metastasis risk in NPC patients.
They enrolled 55 newly diagnosed NPC patients (stages III–IVa) who had not received prior treatment. All got standard chemoradiotherapy. The team measured CD39+CD8+ T cells and related markers (like CD103, PD-1, and Tim-3) in blood samples before treatment, 1 month post-treatment, and 6 months post-treatment. They also tracked progression-free survival (PFS)—the time patients went without their cancer worsening.
Key Findings: More CD39+CD8+ T Cells = Less Metastasis
The results were clear:
- Higher levels before treatment mean less metastasis: Patients who did not develop distant metastasis had 2–3 times higher levels of CD39+CD8+ and CD39+CD103+CD8+ T cells before treatment compared to those who did get metastasis. For example, CD39+CD8+ T cells made up 6.52% of CD8+ T cells in non-metastasis patients vs. just 2.41% in metastasis patients.
- Better survival with high CD39+CD103+CD8+ T cells: Patients with above-median levels of CD39+CD103+CD8+ T cells had longer PFS—they went longer without their cancer progressing. Multivariate analysis confirmed this: high CD39+CD103+CD8+ T cells were linked to a 85% lower risk of progression (hazard ratio = 0.147).
- These cells are functional, not exhausted: Most CD39+CD8+ T cells lacked exhaustion markers like PD-1 (only 11.5% were PD-1+) or Tim-3 (only 4.8% were Tim-3+). This means they’re not worn out—they can still actively fight cancer.
What Happens After Treatment?
The team also looked at how CD39+CD8+ T cells changed after chemoradiotherapy in 21 patients who didn’t get metastasis:
- CD39+CD8+ T cells spike at 1 month: Levels jumped from 5.91% pre-treatment to 10.02% 1 month post-treatment—a 69% increase.
- More “effector memory” T cells: The number of advanced-differentiated CD8+ T cells (called “effector memory” cells) also rose. These cells are “trained” to remember tumors—they can quickly reactivate if cancer comes back. Importantly, the rise in CD39+CD8+ T cells correlated with more effector memory cells—meaning treatment was boosting functional, tumor-specific immune responses.
Why This Matters
Chemoradiotherapy doesn’t just kill cancer cells—it also triggers “immunogenic cell death,” which releases tumor antigens (proteins that tell the immune system “this is cancer”). The spike in CD39+CD8+ T cells after treatment suggests these cells are being activated by those antigens—growing in number and getting ready to fight. Because they’re not exhausted, they can travel through the blood to find and kill spread cancer cells, which is why patients with higher levels have less metastasis.
Limitations and Next Steps
The study had a small number of patients with metastasis (10 total) and a short follow-up period. More research with larger groups and longer follow-up is needed to confirm these findings. But the results are promising: CD39+CD8+ T cells could become a prognostic biomarker for NPC patients—helping doctors identify who’s at high risk of metastasis and who might benefit from additional immune therapies.
Who Did the Research?
The study was led by Dan-Ning Dong (Third Affiliated Hospital of Xinjiang Medical University), Pei-Wen Fan (Xinjiang Key Laboratory of Oncology), and Jin-Ming Yu (Shandong Cancer Hospital and Institute), with contributions from the Chinese Academy of Medical Sciences Oxford Institute at the University of Oxford.
Where to Find the Full Study
You can read the original research here: doi.org/10.1097/CM9.0000000000001745
For NPC patients and doctors, this study offers new hope: a simple blood test for CD39+CD8+ T cells could one day help tailor treatment and predict outcomes. And for researchers, it highlights the potential of these cells for adoptive immunotherapy—taking a patient’s own tumor-specific T cells, growing them in the lab, and putting them back to fight metastasis.
Was this helpful?
0 / 0